Orchestra BioMed (OBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO and Chairperson, with introductions of key officers and the independent auditor present.
Inspector of Election and meeting secretary appointed; agenda and rules of conduct reviewed for orderly proceedings.
Five items of business outlined: director elections, auditor ratification, employee stock plan, executive compensation, and vote frequency.
Board and executive committee updates
Three current directors nominated for re-election to serve three-year terms until the 2029 annual meeting.
Shareholder proposals
No stockholder nominations for directors received; nominations closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Orchestra BioMed
- Pivotal cardiovascular device trials progress with strong partners and funding, targeting 2028 launches.OBIO
Sidoti Small-Cap Virtual Investor Conference18 Jun 2026 - 2026 Employee Stock Purchase Plan approved, enabling employees to acquire up to 750,000 shares.OBIO
Proxy filing16 Jun 2026 - Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven value.OBIO
Jefferies Global Healthcare Conference 20264 Jun 2026 - Pivotal cardiovascular therapies advance toward commercialization with strong partner support.OBIO
Corporate presentation4 Jun 2026 - Net loss widened to $20.7M as R&D spending rose, with cash runway into Q4 2027 and new FDA designation.OBIO
Q1 202613 May 2026 - Board recommends approval of all annual meeting proposals, including compensation and governance.OBIO
Proxy filing29 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.OBIO
Proxy filing29 Apr 2026 - Pivotal cardiovascular therapies advance in global trials, backed by major industry partnerships.OBIO
Corporate presentation1 Apr 2026 - Revenue up 1,539% to $33.5M; strong cash, pivotal trials advancing, more proceeds expected.OBIO
Q4 202512 Mar 2026